Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Mitral Valve Malignant Glomus Tumor Presenting With Multiple Embolic Events.
Journal: JACC. Case reports
Published: June 08, 2026
Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914].
Journal: JTO clinical and research reports
Published: May 21, 2026
Corrigendum to "KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status" [Cancer Treatment and Research Communications 47 (2026) 101227].
Journal: Cancer treatment and research communications
Published: May 16, 2026
Impact of Genomic Subtype on Intracranial Outcomes in Treatment-naive EGFR mutant NSCLC with Osimertinib (IGnITE).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: April 17, 2026
KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status.
Journal: Cancer treatment and research communications
Published: October 07, 2025
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 25, 2025
DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy.
Journal: JTO clinical and research reports
Published: July 28, 2025
Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 08, 2025
Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer.
Journal: Clinical lung cancer
Published: May 23, 2025
Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes.
Journal: JTO clinical and research reports
Published: May 02, 2025
FLAURA2: evidence for escalated first-line therapy in EGFR-mutated non-small cell lung cancer with central nervous system metastases.
Journal: Translational cancer research
Published: December 19, 2024
Last Updated: 09/26/2026